Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients with cervical nodal necrosis. 2017

Mei Lan, and Chunyan Chen, and Ying Huang, and Li Tian, and Zhijun Duan, and Fei Han, and Junfang Liao, and Meiling Deng, and Terence T Sio, and Anussara Prayongrat, and Lie Zheng, and Shaoxiong Wu, and Taixiang Lu
State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Department of Radiation Oncology, Guangzhou, China.

The effectiveness of neoadjuvant chemotherapy (NACT) followed by concurrent chemoradiotherapy (CCRT) compared with CCRT alone in nasopharyngeal carcinoma (NPC) patients who presented with cervical nodal necrosis (CNN) is unknown. A total of 792 patients with stage T1-4N1-3M0 NPC and presented with CNN based on magnetic resonance imaging were retrospectively reviewed. Propensity score matching method was used to balance treatment arms for baseline characteristics. Eventually, 508 patients were propensity-matched on a 1:1 basis to create two groups (NACT + CCRT and CCRT groups). Survival rates were calculated by Kaplan-Meier method and differences were compared by using the log-rank test. The 5-year disease specific survival, disease-free survival and distant metastasis-free survival were significantly higher in NACT + CCRT group relative to the matched CCRT group (82.1% vs. 72.5%, P = 0.021; 70.3% vs. 54.1%, P < 0.001; 81.9% vs. 67.3%, P < 0.001, respectively). Although the rates of grade 3-4 leucopenia and mucositis were higher in NACT + CCRT group than CCRT group, compliance with the combined treatment was good and no significant difference was observed between two groups. NACT followed by CCRT was relatively safe and could achieve better survival than CCRT alone in NPC patients with CNN by reducing the risk of death, tumor progression and distant metastasis.

UI MeSH Term Description Entries
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008279 Magnetic Resonance Imaging Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques. Chemical Shift Imaging,MR Tomography,MRI Scans,MRI, Functional,Magnetic Resonance Image,Magnetic Resonance Imaging, Functional,Magnetization Transfer Contrast Imaging,NMR Imaging,NMR Tomography,Tomography, NMR,Tomography, Proton Spin,fMRI,Functional Magnetic Resonance Imaging,Imaging, Chemical Shift,Proton Spin Tomography,Spin Echo Imaging,Steady-State Free Precession MRI,Tomography, MR,Zeugmatography,Chemical Shift Imagings,Echo Imaging, Spin,Echo Imagings, Spin,Functional MRI,Functional MRIs,Image, Magnetic Resonance,Imaging, Magnetic Resonance,Imaging, NMR,Imaging, Spin Echo,Imagings, Chemical Shift,Imagings, Spin Echo,MRI Scan,MRIs, Functional,Magnetic Resonance Images,Resonance Image, Magnetic,Scan, MRI,Scans, MRI,Shift Imaging, Chemical,Shift Imagings, Chemical,Spin Echo Imagings,Steady State Free Precession MRI
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009303 Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX. Cancer of Nasopharynx,Nasopharyngeal Cancer,Cancer of the Nasopharynx,Nasopharynx Cancer,Nasopharynx Neoplasms,Neoplasms, Nasopharyngeal,Cancer, Nasopharyngeal,Cancer, Nasopharynx,Cancers, Nasopharyngeal,Cancers, Nasopharynx,Nasopharyngeal Cancers,Nasopharyngeal Neoplasm,Nasopharynx Cancers,Nasopharynx Neoplasm,Neoplasm, Nasopharyngeal,Neoplasm, Nasopharynx,Neoplasms, Nasopharynx
D009336 Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas

Related Publications

Mei Lan, and Chunyan Chen, and Ying Huang, and Li Tian, and Zhijun Duan, and Fei Han, and Junfang Liao, and Meiling Deng, and Terence T Sio, and Anussara Prayongrat, and Lie Zheng, and Shaoxiong Wu, and Taixiang Lu
March 2018, BMC cancer,
Mei Lan, and Chunyan Chen, and Ying Huang, and Li Tian, and Zhijun Duan, and Fei Han, and Junfang Liao, and Meiling Deng, and Terence T Sio, and Anussara Prayongrat, and Lie Zheng, and Shaoxiong Wu, and Taixiang Lu
January 2020, Journal of biological regulators and homeostatic agents,
Mei Lan, and Chunyan Chen, and Ying Huang, and Li Tian, and Zhijun Duan, and Fei Han, and Junfang Liao, and Meiling Deng, and Terence T Sio, and Anussara Prayongrat, and Lie Zheng, and Shaoxiong Wu, and Taixiang Lu
April 2017, European journal of cancer (Oxford, England : 1990),
Mei Lan, and Chunyan Chen, and Ying Huang, and Li Tian, and Zhijun Duan, and Fei Han, and Junfang Liao, and Meiling Deng, and Terence T Sio, and Anussara Prayongrat, and Lie Zheng, and Shaoxiong Wu, and Taixiang Lu
November 2015, BMC cancer,
Mei Lan, and Chunyan Chen, and Ying Huang, and Li Tian, and Zhijun Duan, and Fei Han, and Junfang Liao, and Meiling Deng, and Terence T Sio, and Anussara Prayongrat, and Lie Zheng, and Shaoxiong Wu, and Taixiang Lu
February 2012, Anticancer research,
Mei Lan, and Chunyan Chen, and Ying Huang, and Li Tian, and Zhijun Duan, and Fei Han, and Junfang Liao, and Meiling Deng, and Terence T Sio, and Anussara Prayongrat, and Lie Zheng, and Shaoxiong Wu, and Taixiang Lu
June 2018, Oral oncology,
Mei Lan, and Chunyan Chen, and Ying Huang, and Li Tian, and Zhijun Duan, and Fei Han, and Junfang Liao, and Meiling Deng, and Terence T Sio, and Anussara Prayongrat, and Lie Zheng, and Shaoxiong Wu, and Taixiang Lu
January 2015, Annals of oncology : official journal of the European Society for Medical Oncology,
Mei Lan, and Chunyan Chen, and Ying Huang, and Li Tian, and Zhijun Duan, and Fei Han, and Junfang Liao, and Meiling Deng, and Terence T Sio, and Anussara Prayongrat, and Lie Zheng, and Shaoxiong Wu, and Taixiang Lu
May 2024, BMC cancer,
Mei Lan, and Chunyan Chen, and Ying Huang, and Li Tian, and Zhijun Duan, and Fei Han, and Junfang Liao, and Meiling Deng, and Terence T Sio, and Anussara Prayongrat, and Lie Zheng, and Shaoxiong Wu, and Taixiang Lu
February 2024, Head & neck,
Mei Lan, and Chunyan Chen, and Ying Huang, and Li Tian, and Zhijun Duan, and Fei Han, and Junfang Liao, and Meiling Deng, and Terence T Sio, and Anussara Prayongrat, and Lie Zheng, and Shaoxiong Wu, and Taixiang Lu
May 2016, Oncotarget,
Copied contents to your clipboard!